Metabolomic assessment after cells were incubated in a low concentration (0.1 g/L) of 13C6-glucose revealed that U251 control (U251-dCas9-KRAB-MeCP2) cells had less glycolytic (Supplementary Fig. S11A) and TCA (Supplementary Fig. S11B) metabolites than U251 CD97 knockdown (U251-dCAS9-KRAB-MeCP2-CD97sgRNA) cells, suggesting that, despite the energy requirements associated with the proliferative pathways it activates, in GBM cells, CD97 slowed metabolic flux. The gene discussed is MECP2; the disease is glioblastoma.